Here are some of the new drugs being researched for pulmonary arterial hypertension (PAH):

1. Imatinib (Inhalable Version)
- Type: Tyrosine Kinase Inhibitor
- Details: Currently FDA-approved for multiple forms of cancer. Researchers are studying an inhalable version to treat PAH, which may reduce the side effects Show Full Answer

Here are some of the new drugs being researched for pulmonary arterial hypertension (PAH):

1. Imatinib (Inhalable Version)
- Type: Tyrosine Kinase Inhibitor
- Details: Currently FDA-approved for multiple forms of cancer. Researchers are studying an inhalable version to treat PAH, which may reduce the side effects associated with the oral version.

2. Seralutinib
- Type: Tyrosine Kinase Inhibitor
- Details: Tested for its efficacy and safety in treating PAH. The final safety and efficacy trial was completed in August 2023, and the drug is scheduled for FDA approval in 2024.

3. Elafin
- Type: Enzyme Blocker
- Details: A subcutaneous injection that blocks elastin, an enzyme with higher levels in those diagnosed with PAH. It has shown promise in reversing blood vessel changes caused by PAH in animal studies and is undergoing further trials in humans.

4. Apabetalone
- Type: Bromodomain Inhibitor
- Details: An oral medication that reduces inflammation in the body due to PAH. A small 2022 study showed it reduced damaging cellular changes.

These drugs are still under research, and further studies are needed to confirm their efficacy and safety for PAH treatment. Always consult with your doctor for the most appropriate treatment options for your condition.

 This AI-generated response comes from myPHteam and other selected sources. It is not a substitute for medical advice. Always ask your doctor about specific health concerns.

New Pulmonary Arterial Hypertension Medications: 4 Advances in Treatment | myPHteam